Phase 2 N=2 Adjuvant Proton Therapy or IMRT for the Treatment of Bladder Cancer
Urothelial Carcinoma of the Bladder
Primary: Number of Participants With Adverse Events — 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis
Penile Cancer
Primary: Number of Participants With Pathologic Complete Remission (pCR) — 3 participants
N/A N=25 MRI- Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer
MRI Guided Transurethral Ultrasound Ablation · Localized Prostate Cancer · Ablation Therapy
Primary: Absence of Clinically Significant Cancer (CSC) on Control Biopsy at 1-year Follow-up. — 8 Participants
N/A N=24 Drainage of Malignant Extrinsic Ureteral Obstruction Using the Memokath Ureteral Stent
Ureteral Obstruction
Primary: Mean Stent Dwell Time — 17; 3.97 months
Phase 2 N=36 First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma
Urothelial Carcinoma
Primary: Median Overall Survival — 13.9 months
Phase 2 N=17 Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)
Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
Primary: Number of Participants With Progression-free Survival at 6 Months — 3 Participants
Phase 2 N=15 Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract
Non-Transitional Cell Carcinoma of the Urothelial Tract · Small Cell of the Bladder · Adenocarcinoma of the Bladder
Primary: Overall Response Rate — 2; 11; 2 Participants
Phase 2 N=22 Study of Docetaxel and Oxaliplatin in Metastatic Transitional Cell Cancer (TCC) of the Urothelial Tract
Metastatic Transitional Cell Cancer of the Urothelial Tract
Primary: Response Rate — 11 percentage of participants
Phase 2 N=37 Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer
Bladder Cancer
Primary: Percentage of Participants Free From Radical Cystectomy at 3 Years — 88.2 percentage of participants
N/A N=20 Merits of Performing a Modified Template Retroperitoneal Lymph Node Dissection
Cancer of the Urinary Tract
Primary: Number of Participants With Pathologically Proven Lymph Node Metastasis — 1 participants
Phase 2 N=32 Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach
Invasive Bladder Cancer
Primary: Proportion of Patients With Pathological Response — 26; 2 Participants
Phase 2 N=135 Vessel Sparing Prostate Radiation Therapy
Cancer of the PROSTATE
Primary: The Percentage of Patients Able to be Sexually Active With or Without the Use of Aids — 88 percentage of patients
N/A N=228 Proton Therapy for Low and Intermediate Risk Prostate Cancer
Prostate Cancer
Primary: Acute Grade 3 (NCI CTC v4.0) or Higher Treatment-related Toxicity Rate. — 0; 0 Participants
Phase 2 N=45 Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus
Epidermoid Carcinoma · Anus
Primary: Percentage of Patients With Complete Response to Treatment — 30; 10; 0; 4 Participants
N/A N=42 Assessment of the Effectiveness of Local Ablathermy Radio Frequency Bronchial Tumors Primitive
Malignant Non-small Cell Neoplasm of Lung Stage Ia
Primary: Local Tumor Control Rate 1 Year After Percutaneous Radiofrequency Ablation (RFA) — 5 Participants
N/A N=22 Proton Beam Teletherapy for Post-Hysterectomy Cancers of the Uterus and Cervix
Uterine Cancer · Cervical Cancer
Primary: Dosimetric Comparison of Proton Beam Treatment With 3-dimensional Conformal Radiation Therapy (3DCRT) and Intensity Modulated Radiation Therapy (IMRT) — 455.0; 149.0…
Phase 2 N=36 Evaluation of NanoDoce® in Participants With Urothelial Carcinoma
Bladder Cancer · Urothelial Carcinoma · Urinary Bladder Neoplasm
Primary: Incidence of Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 3; 9 Participants
Phase 2 N=49 Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer
Metastatic Urothelial Cancer
Primary: Objective Response Rate (ORR) — 69.6; 33.3 Percentage of participants
Phase 2 N=11 Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Transitional Cell Carcinoma of the Bladder
Bladder Cancer
Primary: Median Yield of Robot Assisted and Second Look Open Pelvic Lymph Node Dissection to Compare the Lymph Node Yield Achieved — 43; 4 Nodes (Node Yield)
N/A N=12 Erectile Rating During the Treatment of Rectal Cancers Localized
Rectal Cancer Stage I
Primary: Proportion of Patients With Erectile Dysfunction Induced by Medical and Surgical Treatment of Rectal Cancer — 0 Participants
Phase 2 N=19 Pazopanib in Treating Patients With Metastatic Urothelial Cancer
Distal Urethral Cancer · Proximal Urethral Cancer · Recurrent Bladder Cancer
Primary: Best Tumor Response (Complete [CR] or Partial Response [PR] by Response Evaluation Criteria in Solid Tumors [RECIST]) — 0; 0 participants
Phase 2 N=51 The Role of 68Ga-PSMA-11 PET (Prostate Specific Membrane Antigen) in Surgery Guidance in Prostate Cancer
Prostate Cancer
Primary: Sensitivity of PSMA-PET and MRI Imaging Preoperatively for Predicting Extra-prostatic Extension — 86; 57 percentage — p=<0.05
Phase 2 N=14 Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
Urothelial Carcinoma
Primary: Overall Response Rate — 11 Participants
N/A N=40 Study to Determine Effects of Vesicare on Return to Continence Post - Radical Prostatectomy (Part II)
Urinary Incontinence
Primary: Time to Continence — 95 Days to Continence
Phase 2 N=83 Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects
Urothelial Carcinoma · Bladder Cancer
Primary: Phase Ib: Safety of Pembrolizumab in Combination With Gemcitabine-Cisplatin — 0 Participants
Phase 2 N=28 Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer
Bladder Cancer
Primary: The Number of Participants Experiencing an Unacceptable Level of Toxicity as Defined Below — 9; 6; 2; 4 Participants
Phase 2 N=78 Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
Bladder Cancer · Transitional Cell Cancer of the Renal Pelvis and Ureter · Urethral Cancer
Primary: Overall Objective Response — 3; 29; 39 participants
Phase 2 N=29 Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma
Urothelial Carcinoma
Primary: Bladder Tumor Recurrence Rate — 41.37 percentage of subjects
Phase 2 N=28 Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
Newly Diagnosed Oligometastatic Prostate Cancer
Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants
Phase 2 N=69 Cabozantinib for Advanced Urothelial Cancer
Urothelial Carcinoma · Urethral Neoplasms · Urinary Bladder Neoplasms
Primary: Percentage of Participants With Overall Response — 19.1; NA; NA percentage of participants